Canine Atopic Dermatitis Market Report 2026

Canine Atopic Dermatitis Market Overview

• Canine Atopic Dermatitis market size has reached to $2.76 billion in 2025 • Expected to grow to $4.5 billion in 2030 at a compound annual growth rate (CAGR) of 10.2% • Growth Driver: Rising Incidence Of Skin Allergies Fueling The Growth With Increasing Allergen Exposure • Market Trend: Regulatory Approvals Drive Global Expansion And Innovation In Canine Atopic Dermatitis Treatments • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Canine Atopic Dermatitis Market?

Canine atopic dermatitis is a chronic, inflammatory skin disease in dogs caused by an allergic reaction to environmental allergens such as pollen, dust mites, mold, or certain foods. It is a genetic condition that leads to intense itching, redness, and recurring skin infections. The primary purpose of treating canine atopic dermatitis is to relieve itching, reduce inflammation, and manage secondary infections to improve the dog’s quality of life. The main types of products in managing canine atopic dermatitis include glucocorticoids, antihistamines, immunosuppressants, monoclonal antibodies (mAbs), and other related treatments. Glucocorticoids are synthetic, broad-spectrum hormones that effectively reduce itching and inflammation by dampening the immune system’s response. The condition affects various dog breeds, such as german shepherds, terriers, retrievers, and others, with indications including ectoparasites, food allergies, allergic skin infections, and more. The treatments are administered through different routes, such as oral, topical, and injectable, and are distributed through veterinary clinics, retail pharmacies, online pharmacies, and other distribution channels.

What Is The Canine Atopic Dermatitis Market Growth Forecast?

The canine atopic dermatitis market size is expected to see rapid growth in the next few years. It will grow to $4.5 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to development of novel biologics and mAbs, increasing investments in precision medicine for pets, rising adoption of topical and systemic immunotherapies, growth in online and retail distribution channels, focus on preventive and supportive care including nutraceuticals. Major trends in the forecast period include increasing use of monoclonal antibodies (mabs) for targeted therapy, growing adoption of allergen-specific immunotherapy (asit) in dogs, rising demand for medicated shampoos and topical treatments, expansion of nutraceuticals and probiotics for skin barrier support, focus on breed-specific treatment approaches for canine atopic dermatitis.

Global Canine Atopic Dermatitis Market Segmentation

1) By Product: Glucocorticoids, Antihistamines, Immunosuppressants, Monoclonal Antibodies (mAbs), Other Products 2) By Dog Breed: German Shepherd, Terriers, Retrievers, Other Dog Breeds 3) By Indication: Ectoparasites, Food Allergy, Allergic Skin Infections, Other Indications 4) By Route Of Administration: Oral, Topical, Injectable 5) By Distribution Channel: Veterinary Clinics, Retail Pharmacies, Online Pharmacies, Other Distribution Channels Subsegments: 1) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone 2) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine 3) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil 4) By Monoclonal Antibodies: Lokivetmab, Investigational Monoclonal Antibodies 5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics

What Are The Drivers Of The Canine Atopic Dermatitis Market?

The increasing cases of skin allergies in dogs are expected to propel the growth of the canine atopic dermatitis market going forward. Skin allergies in dogs refer to abnormal immune responses to allergens such as pollen, food, or flea bites, resulting in symptoms like itching, redness, and skin irritation. The rise in skin allergy cases in dogs is partly attributed to increased exposure to environmental pollutants and allergens, which can trigger heightened immune responses and skin irritation. Canine atopic dermatitis treatment helps manage skin allergies in dogs by reducing inflammation and itching and preventing secondary infections, thereby improving their comfort and skin health. For instance, in January 2024, according to the National Institutes of Health (NIH), a US-based government agency, a total of 7,915 dog owners (28.7%) reported that their dogs had a history of skin-related conditions. The prevalence of reported skin issues increased consistently with age, starting at 7% in puppies and rising to 37% in senior dogs. Therefore, the increasing cases of skin allergies in dogs are driving the growth of the canine atopic dermatitis industry. The rising pet ownership is expected to propel the growth of the canine atopic dermatitis market going forward. Pet ownership refers to the act of having and caring for a domesticated animal, such as a dog, cat, bird, or other companion animal, as part of a household. The rise in pet ownership is due to increasing humanization of pets, animals are treated as family members, driving demand for companionship and emotional support. Treating canine atopic dermatitis is beneficial for pets, as it relieves chronic itching and inflammation, improves skin health, and enhances their overall comfort and quality of life. For instance, in April 2025, according to the American Pet Products Association (APPA), a US-based trade association that manufactures and supplies pet products, 94 million US households (71%) own a pet in 2025, an increase from 86.9 million US households (66%) that owned a pet in 2023-2024. Therefore, the rising pet ownership is driving the growth of the canine atopic dermatitis industry.

Key Players In The Global Canine Atopic Dermatitis Market

Major companies operating in the canine atopic dermatitis market are Merck & Co. Inc., Zoetis Inc., Hill’s Pet Nutrition Inc., Royal Canin SAS, Ceva Santé Animale S.A., Virbac S.A., Elanco Animal Health Inc., Dechra Pharmaceuticals PLC, Vetoquinol S.A., Bioiberica S.A.U., Bimeda Animal Health Limited, Animal Dermatology Group Inc., Kindred Biosciences Inc., Nextmune AB, OKAVA Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Toray Industries Inc., LEO Pharma A/S, PetIQ Inc., Hester Biosciences Limited, Ourofino Saude Animal, Swedencare AB, Orion Corporation, Norbrook Laboratories Ltd., AB Science SA.

Global Canine Atopic Dermatitis Market Trends and Insights

Major companies operating in the canine atopic dermatitis market are focusing on obtaining regulatory approvals to expand the availability and adoption of their therapies across global markets. Regulatory approvals refer to the official permissions granted by government health authorities that allow companies to market and sell their medical products after proving their safety, efficacy, and quality through rigorous testing. For instance, in September 2024, Elanco Animal Health Inc., a US-based pharmaceutical company specializing in animal health, received US FDA approval for Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitis. The approval of Zenrelia marks a significant advancement in managing itchy dogs dealing with chronic, acute, or seasonal itch and inflammation, all in a single, once-daily tablet from the outset. It works by targeting the source of itch, blocking the pathways responsible for allergic itch to interrupt the itch-scratch cycle. Zenrelia delivers visible improvement from the initial dose and reduces the likelihood of rebound itch, a common issue in many dogs treated with the competing JAK inhibitor.

Regional Outlook

North America was the largest region in the canine atopic dermatitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Canine Atopic Dermatitis Market?

The canine atopic dermatitis market consists of sales of products including medicated shampoos, hypoallergenic diets, omega-3 fatty acid supplements, skin barrier repair creams, and topical antimicrobial or antifungal treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.